Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial

JAMA

Volumn 279, Issue 16, 1998, Pages 1265-1272

  Adams, Harold P ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; HEPARINOID;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INJURY SCALE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

EID: 2642713359     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.16.1265     Document Type: Article

References (36)

1. Marsh EE III, Adams HP Jr, Biller J, et al. Use of antithrombotic drugs in the treatment of acute ischemic stroke: a survey of neurologists in practice in the United States. Neurology. 1989;39:1631-1634.
2. Sherman DG, Dyken ML Jr, Gent M, Harrison MJG, Hart RG, Mohr JP. Antithrombotic therapy for cerebrovascular disorders: an update. Chest. 1995;108(suppl):444S-456S.
3. Adams HP Jr, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke. Stroke. 1994;25:1901-1914.
4. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke. 1983;14:668-676.
5. Duke RJ, Bloch RF, Turpie AGG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke: a randomized controlled trial. Ann Intern Med. 1986; 105:825-828.
6. Sandercock PAG, van den Bolt AGM, Lindley RI, Slatery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry. 1993;56:17-25.
7. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet. 1997;349:1569-1581.
8. Kay RJ, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333:1588-1593.
9. Bradbrook ID, Magnani HN, Moelker HCT, et al. ORG 10172, a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol. 1987;3:667-675.
10. Danhof M, de Boer A, Magnani HN, Stiekema JCJ. Pharmacokinetic considerations on Orgaran (ORG 10172) therapy. Haemostasis. 1992;22:73-84.
11. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (ORG 10172). Thromb Haemost. 1993;70: 554-561.
12. Turpie AGG, Gent M, Cote R, et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with ischemic stroke: a randomized, double-blind study. Ann Intern Med. 1992; 117:353-357.
13. Biller J, Massey EW, Marler JR, et al. A dose escalation study of ORG 10172 (low molecular weight heparinoid) in stroke. Neurology. 1989;39: 262-265.
14. Massey EW, Biller J, Davis JN, et al. A study of large dose infusions of heparinoid ORG 10172 in ischemic stroke. Stroke. 1990;21:1289-1292.
15. Adams HP Jr, Woolson RF, Clarke WR, et al. Design of the Trial of ORG 10172 in Acute Stroke Treatment (TOAST). Control Clin Trials. 1997;18:358-377.
16. Albanese M, Clarke WR, Adams HP Jr, Woolson RF, and the TOAST Investigators. Ensuring reliability of outcome measures in multicenter clinical trials of treatments of acute ischemic stroke: the program developed for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST). Stroke. 1994;25:1746-1751.
17. Jennet B, Bond M. Assessment of outcome after severe brain damage: a practical scale. Lancet. 1975; 1:480-484.
18. Mahoney FI, Barthel DW. Function evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
19. Wade DE. Measurement in Neurologic Rehabilitation. Oxford, England: Oxford University Press; 1992.
20. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1588-1593.
21. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
22. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtypes of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke. 1993;23:35-41.
23. 2 tests. Biometrics. 1954;10:417-451.
24. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;2:719-748.
25. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons Inc; 1980.
26. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70: 659-663.
27. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrika. 1979;35: 549-556.
28. Woolson RF. Statistical Methods for the Analysis of Biomedical Data. New York, NY: John Wiley & Sons Inc; 1987.
29. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-1649.
30. Hornig CR, Bauer T, Simon C, Trittmacher S, Dorndorf W. Hemorrhagic transformation in cardio-embolic cerebral infarction. Stroke. 1993;4:465-468.
31. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
32. Camerlingo M, Casto L, Censori B, et al. Immediate anticoagulation with heparin for first-ever ischemic stroke in the carotid artery territories observed within hours of onset. Arch Neurol. 1994;51: 462-467.
33. Chammaro A, Vila N, Saiz A, Alday M, Tolosa E. Early anticoagulation after large cerebral embolic infarction. Neurology. 1995;45:861-865.
34. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med. 1993;119:874-881.
35. Gordon DL, Bendixen BH, Adams HP Jr, et al. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. Neurology. 1993;43:1021-1027.
36. Madden KP, Karanjia PN, Adams HP Jr, Clarke WR, and the TOAST Investigators. Accuracy of initial stroke subtype diagnosis in the TOAST study. Neurology. 1995;45:1975-1979.